Asian Pacific Journal of Cancer Prevention

  • 제15권14호
  • /
  • Pages.5945-5950
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Bevacizumab Concomitant with Chemotherapy is Effective in Treating Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

  • Sun, Jing (Department of Medical Oncology, Chinese PLA General Hospital) ;
  • Hu, Yi (Department of Medical Oncology, Chinese PLA General Hospital) ;
  • Wu, Bai-Shou (Department of Medical Oncology, Chinese PLA General Hospital) ;
  • Wang, Jin-Liang (Department of Medical Oncology, Chinese PLA General Hospital) ;
  • Tao, Hai-Tao (Department of Medical Oncology, Chinese PLA General Hospital) ;
  • Zhang, Su-Jie (Department of Medical Oncology, Chinese PLA General Hospital)
  • 발행 : 2014.07.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: To retrospectively review the safety and clinical efficacy of bevacizumab concomitant with chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer (NSNSCLC). Methods: Clinical data for 79 patients with NSNSCLC who received bevacizumab concomitant with chemotherapy in Chinese PLA General Hospital from April 28th 2009 to May 5th 2013 were retrospectively reviewed to analyze the clinical efficacy including disease control rate (DCR), overall response rate (ORR), progression-free survival (PFS), overall survival (OS), the Eastern Cooperative Oncology Group (ECOG) score and the safety. Results: The Eastern Cooperative Oncology Group (ECOG) score was 0-2. By the final cutoff date (June 9, 2013), 54 (68.4%) patients had disease progression and 37 (46.8%) died. The ORR was 32.9% and the DCR was 83.5%. The ORR of the first-, second-, and third- or later-line treatments were 51.4%, 25.0% and 12.5%, while the DCR were 94.3%, 80.0% and 70.8%, respectively. The median OS (mOS) and PFS (mPFS) were 13.5 and 5.83 months, respectively. The mOS of patients with the first-, second-, and third- or later- line treatments were 16.2, 10.9 and 8.30 months, while the mPFS were 7.27, 5.90 and 5.17 months, respectively. Chemotherapy-related adverse events included myelosuppression, vomiting, hepatic dysfunction and renal dysfunction, while the common serious bevacizumab-related adverse events were thromboembolic problems, gastrointestinal perforation and reversible posterior leukoencephalopathy syndrome, which could be well managed. Conclusions: Bevacizumab concomitant with chemotherapy is effective and the related toxicity can be well tolerated in Chinese patients with NSNSCLC.

키워드

참고문헌

  1. Adjei AA, Mandrekar SJ, Dy GK et al (2010). Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol, 28, 614-9. https://doi.org/10.1200/JCO.2009.23.6406
  2. Cirillo M, Venturini M, Ciccarelli L, et al (2009). Clinician versus nurse symptom reporting using the National Cancer Institute Common Terminology Criteria forAdverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol, 20, 1929-35. https://doi.org/10.1093/annonc/mdp287
  3. Cohen MH, Shen YL, Keegan P, et al (2009). FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblas-toma multiforme. Oncologist, 14, 1131-8. https://doi.org/10.1634/theoncologist.2009-0121
  4. Crino L, Dansin E, Garrido P, et al (2010). Safety and efficacy of first-line bevacizumab-based therapy in advanced nonsquamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol, 11, 733-40. https://doi.org/10.1016/S1470-2045(10)70151-0
  5. Eisenhauer EA, Therasse P, Bogaerts J et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  6. Emal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-249. https://doi.org/10.3322/caac.20006
  7. Ferrara N, Hillan KJ, Gerber HP et al (2004). Discovery and development of bev-acizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391-400. https://doi.org/10.1038/nrd1381
  8. Habib S, Delourme J, Dhalluin X, Petyt G et al (2013). Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study. Lung Cancer, 80, 197-202. https://doi.org/10.1016/j.lungcan.2013.01.015
  9. Heist RS, Fidias P, Huberman M et al (2008). Aphase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol, 3, 1153-8. https://doi.org/10.1097/JTO.0b013e318187273f
  10. Herbst RS, O'Neill VJ, Fehrenbacher L et al (2007). Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol, 25, 4743-50. https://doi.org/10.1200/JCO.2007.12.3026
  11. Huang XE, Tian GY, Cao J, et al (2013). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7. https://doi.org/10.7314/APJCP.2013.14.11.6663
  12. Johnson DH, Fehrenbacher L, Novotny WF et al (2004). Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 22, 2184-91. https://doi.org/10.1200/JCO.2004.11.022
  13. Juergens R, Brahmer J (2007). Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep, 9, 255-64. https://doi.org/10.1007/s11912-007-0031-2
  14. Kerbel R, Folkman J (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2, 727-39. https://doi.org/10.1038/nrc905
  15. Kitamura K, Kubota K, Ando M, Takahashi S et al (2013). Bevacizumab plus chemotherapy for advanced nonsquamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol, 71, 457-61. https://doi.org/10.1007/s00280-012-2026-4
  16. Lilenbaum R, Raez L, Tseng J, et al (2008). Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol, 3, 511-5. https://doi.org/10.1097/JTO.0b013e31816de28f
  17. Liu HZ, Peng J, Zheng F, et al (2013). Lack of assocation of glutathione S-transferase T1 gene null and susceptibility to lung cancer in china: a meta-analysis. Asian Pac J Cancer Prev, 14, 7215-9. https://doi.org/10.7314/APJCP.2013.14.12.7215
  18. Ma CH, Jiang R, Li JD, et al (2013). Experimental study of Endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts. Asian Pac J Cancer Prev, 14, 6697-701. https://doi.org/10.7314/APJCP.2013.14.11.6697
  19. Mohammad RY, Somayyeh G, Gholamreza H, et al (2013). Diosgenin inhibits hTERT gene expression in the A549 lung cancer cell line. Asian Pac J Cancer Prev, 14, 6945-8. https://doi.org/10.7314/APJCP.2013.14.11.6945
  20. Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-8. https://doi.org/10.7314/APJCP.2013.14.11.6925
  21. Niho S, Kunitoh H, Nokihala H, et al (2012). Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small cell lung cancer. Lung Cancer, 76, 362-7. https://doi.org/10.1016/j.lungcan.2011.12.005
  22. Reck M, Von-Pawel J, Zatloukal P, et al (2009). Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall- cell lung cancer: AVAiL. J Clin Oncol, 27, 1227-34. https://doi.org/10.1200/JCO.2007.14.5466
  23. Reck M, von Pawel J, Zatloukal P, et al (2010). Overall survival with cisplatin gemcitabine and bevacizumab or placebo as first-line therapy for non squamous non-small cell lung cancer: results from a randomized phase III trial (AVAIL). Ann Oncol, 21, 1804-9. https://doi.org/10.1093/annonc/mdq020
  24. Sandler A, Gray R, Perry MC et al (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355, 2542-50. https://doi.org/10.1056/NEJMoa061884
  25. Sandler A, Yi J, Hambleton J, et al (2010). Treatment outcome by tumor histology in Easten Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplation (PC) for advanced non-small cell lung cancer (NSCLC). J Thorac Oncol, 5, 16-23.
  26. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  27. Soerjomataram L, Lortet-Tieulent J, Parkin DM, et al (2012). Global burden of cancer in 2008, a systematic analysis of disabelity-adjusted life-year in 12 world regions. Lancet, 380, 1840-50. https://doi.org/10.1016/S0140-6736(12)60919-2
  28. Stinchcombe TE, Socinski MA (2009). Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc, 6, 233-41. https://doi.org/10.1513/pats.200809-110LC
  29. Summers J, Cohen MH, Keegan P, et al (2010). FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist, 15, 104-11. https://doi.org/10.1634/theoncologist.2009-0250
  30. Wang H, Gui SY, Chen FH, et al (2013). New insights into 4-amino-2-tri-fluoromethyl-phenyl ester inhibition of cell growth and migration in the A549 lung adenocarcinoma cell line. Asian Pac J Cancer Prev, 14, 7265-70. https://doi.org/10.7314/APJCP.2013.14.12.7265
  31. Wu W, Xu L, Liu Z, et al (2009). Acceptable safety of bevacizumab therapy in combination with chemotherapy in patients with advanced lung cancer. Zhongguo Fei Ai Za Zhi, 12, 231-5.
  32. Xu TP, Zhu CH, Zhang J, et al (2013). MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pac J Cancer Prev, 14, 7085-90. https://doi.org/10.7314/APJCP.2013.14.12.7085
  33. Zhang XJ, Zhang TY, Yu FF, et al (2013). Risk of treatmentrelated mortality with sorafenib in patients with cancer. Asian Pac J Cancer Prev, 14, 6681-6. https://doi.org/10.7314/APJCP.2013.14.11.6681

피인용 문헌

  1. XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10375
  2. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer pp.17597706, 2018, https://doi.org/10.1111/1759-7714.12886
  3. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer vol.9, pp.7, 2018, https://doi.org/10.1111/1759-7714.12650